MST1R and cancer: Indeed, agents targeting c-Met and RON for cancer therapy are FDA approved or are in various phases of clinical trials and/or pre-clinical testing and these include small molecular weight kinase inhibitors and neutralizing antibodies to the receptors or their ligands [3, 22-28].